Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 501

Related Citations for PubMed (Select 19726788)


Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.

Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.


Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.

Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL, de Sauvage FJ.

Cancer Res. 2011 Jan 15;71(2):435-44. doi: 10.1158/0008-5472.CAN-10-2876. Epub 2010 Dec 1.


Clinical experience with Hedgehog pathway inhibitors.

Low JA, de Sauvage FJ.

J Clin Oncol. 2010 Dec 20;28(36):5321-6. doi: 10.1200/JCO.2010.27.9943. Epub 2010 Nov 1.


Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.

Metcalfe C, de Sauvage FJ.

Cancer Res. 2011 Aug 1;71(15):5057-61. doi: 10.1158/0008-5472.CAN-11-0923. Epub 2011 Jul 19. Review. Erratum in: Cancer Res. 2011 Sep 15;71(18):6087.


Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.

Kean S.

Science. 2009 Sep 4;325(5945):1188. doi: 10.1126/science.325_1188. No abstract available.


Hedgehog pathway inhibition and the race against tumor evolution.

Atwood SX, Chang AL, Oro AE.

J Cell Biol. 2012 Oct 15;199(2):193-7. doi: 10.1083/jcb.201207140.


Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.

Rohner A, Spilker ME, Lam JL, Pascual B, Bartkowski D, Li QJ, Yang AH, Stevens G, Xu M, Wells PA, Planken S, Nair S, Sun S.

Mol Cancer Ther. 2012 Jan;11(1):57-65. doi: 10.1158/1535-7163.MCT-11-0691. Epub 2011 Nov 14.


Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.


GDC-0449--targeting the hedgehog signaling pathway.

Dierks C.

Recent Results Cancer Res. 2010;184:235-8. doi: 10.1007/978-3-642-01222-8_17. Review.


Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened.

Tao H, Jin Q, Koo DI, Liao X, Englund NP, Wang Y, Ramamurthy A, Schultz PG, Dorsch M, Kelleher J, Wu X.

Chem Biol. 2011 Apr 22;18(4):432-7. doi: 10.1016/j.chembiol.2011.01.018.


Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH Jr, Beachy PA, Rudin CM.

Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013 Jan 3.


Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.

Scales SJ, de Sauvage FJ.

Trends Pharmacol Sci. 2009 Jun;30(6):303-12. doi: 10.1016/ Epub 2009 May 13. Review.


Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M.

Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599.


Targeting the Hedgehog pathway in cancer: can the spines be smoothened?

Ailles L, Siu LL.

Clin Cancer Res. 2011 Apr 15;17(8):2071-3. doi: 10.1158/1078-0432.CCR-11-0211. Epub 2011 Mar 2.


Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2.

Abe Y, Oda-Sato E, Tobiume K, Kawauchi K, Taya Y, Okamoto K, Oren M, Tanaka N.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4838-43. doi: 10.1073/pnas.0712216105. Epub 2008 Mar 21.


Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E.

Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22.


PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.

Metcalfe C, Alicke B, Crow A, Lamoureux M, Dijkgraaf GJ, Peale F, Gould SE, de Sauvage FJ.

Cancer Res. 2013 Dec 1;73(23):7034-42. doi: 10.1158/0008-5472.CAN-13-1222. Epub 2013 Oct 23.


1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.

Miller-Moslin K, Peukert S, Jain RK, McEwan MA, Karki R, Llamas L, Yusuff N, He F, Li Y, Sun Y, Dai M, Perez L, Michael W, Sheng T, Lei H, Zhang R, Williams J, Bourret A, Ramamurthy A, Yuan J, Guo R, Matsumoto M, Vattay A, Maniara W, Amaral A, Dorsch M, Kelleher JF 3rd.

J Med Chem. 2009 Jul 9;52(13):3954-68. doi: 10.1021/jm900309j.


Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor.

Sasai K, Romer JT, Kimura H, Eberhart DE, Rice DS, Curran T.

Cancer Res. 2007 Apr 15;67(8):3871-7. Epub 2007 Apr 5.


Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD.

Clin Cancer Res. 2011 Apr 15;17(8):2502-11. doi: 10.1158/1078-0432.CCR-10-2745. Epub 2011 Feb 7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk